Next 10 |
home / stock / tngx / tngx articles
BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discoveri...
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discoverin...
BOSTON, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to dis...
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discoverin...
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session...
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Tuesday. Here are some big stocks recording gains in today’s session...
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreeme...
Gainers OpGen, Inc. (NASDAQ: OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received a...
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first...
News, Short Squeeze, Breakout and More Instantly...
Tango Therapeutics Inc. Company Name:
TNGX Stock Symbol:
NASDAQ Market:
– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation...
– Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – –...